1h Free Analyst Time
The Biomarkers Market size was estimated at USD 60.67 billion in 2023, USD 68.98 billion in 2024, and is expected to grow at a CAGR of 14.19% to reach USD 153.67 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
The usage of biomarkers is significantly growing to track the presence or progression of diseases and the effectiveness of treatments. These biomarkers are enabled to track and predict patient health conditions, including blood pressure or cholesterol levels. Moreover, cancer biomarkers can be utilized for diagnosis, prognosis and help to estimate cancer stage, subtype, and prediction for treatment response. These biomarkers are essential for the development of personalized or precision medicine. Additionally, these biomarkers are used in drug development processes for various purposes, including identifying the mechanism of action of drugs, drug target selection, enrichment, dose selection, safety assessment, efficacy assessment, and preclinical safety assessment. Furthermore, the need for biomarkers testing is increasing to enhance the monitoring treatment of chronic disease by detecting or confirming the presence of a disease. However, high production costs and difficulties in collecting and preserving samples in biomarkers procedures are hampering the market's growth. Moreover, advancements in the development of cancer prognostic and diagnostic biomarkers are catering to opportunities for market growth.
Regional Insights
The growing cases of chronic diseases across the Americas has increased the need for biomarkers that allow researchers and clinicians to define the status of a disease which further develops novel therapies. The American Cancer Society estimated approximately 1.9 million new diagnosed cancers in 2022, which further expanded the usage of biomarkers for the development of personalized medicine. Additionally, the U.S. and UK governments are heavily investing in the research and development (R&D) in various areas, including tumor profiling, to improve cancer care and develop biomarkers for more effective drugs. In addition, government funding for research and development and increasing the number of clinical trials across Asia-Pacific countries, such as China, India, Vietnam, and South Korea, are expected to create opportunities for the biomarkers market across Asia-Pacific region.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Biomarkers Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biomarkers Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alto Neuroscience,Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BIOINFRA Life Science Inc., BioStarks, BioVision Inc., Charles River Laboratories, Inc., Clarigent Corporation, EKF Diagnostics Holdings PLC, Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Renalytix PLC, Siemens Healthcare GmbH, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc.Market Segmentation & Coverage
This research report categorizes the Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- Efficacy
- Pharmacodynamics
- Predictive
- Prognostic
- Safety
- Surrogate
- Validation
- Product & Service
- Consumables
- Services
- Software
- Disease
- Cancer
- Cardiovascular Diseases
- Immunological Diseases
- Infectious Diseases
- Neurological Diseases
- Application
- Diagnostic
- Disease Risk Assessment
- Drug Discovery & Development
- Personalized Medicine
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as
- What is the market size and forecast of the Biomarkers Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biomarkers Market?
- What are the technology trends and regulatory frameworks in the Biomarkers Market?
- What is the market share of the leading vendors in the Biomarkers Market?
- Which modes and strategic moves are suitable for entering the Biomarkers Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Biomarkers Market, by Type
7. Biomarkers Market, by Product & Service
8. Biomarkers Market, by Disease
9. Biomarkers Market, by Application
10. Americas Biomarkers Market
11. Asia-Pacific Biomarkers Market
12. Europe, Middle East & Africa Biomarkers Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Alto Neuroscience,Inc.
- APIS Assay Technologies Limited
- Augurex Life Sciences Corp
- Bio-Rad Laboratories, Inc.
- BioAgilytix
- Biocrates Life Sciences AG
- Biofourmis Inc.
- Biognosys AG
- BIOINFRA Life Science Inc.
- BioStarks
- BioVision Inc.
- Charles River Laboratories, Inc.
- Clarigent Corporation
- EKF Diagnostics Holdings PLC
- Elo Health, Inc.
- F. Hoffmann-La Roche, Ltd.
- Merck KgaA
- Nightingale Health Plc
- Owkin Inc.
- Owlstone Medical Limited
- PerkinElmer, Inc.
- Personalis, Inc.
- Proteomedix AG
- QIAGEN GmbH
- Renalytix PLC
- Siemens Healthcare GmbH
- Sino Biological Inc.
- Thermo Fisher Scientific, Inc.
- VivoSense, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 189 |
| Published | March 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 68.98 Billion |
| Forecasted Market Value ( USD | $ 153.67 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
